Teleflex Inc (TFX)
NYSE:TFX
Want to see TFX full AI Analyst Report?
Top Page
Teleflex
(NYSE:TFX)
Select Model
Select Model
Rating:57Neutral
Price Target:
$138.00
▲(4.88% Upside)
Action:ReiteratedDate:05/01/26
The score is held back primarily by weak TTM financial performance, including a large net loss and negative free cash flow. Offsetting factors include strong technical momentum and an earnings-call narrative that outlines a credible path to improved margins and shareholder returns, but with meaningful near-term headwinds and execution/timing risk around divestitures, stranded costs, and planned capital deployment.
Positive Factors
Recurring consumable business model
Teleflex’s portfolio is concentrated in single‑use devices across high‑acuity therapy areas, creating recurring purchase cycles tied to procedure volumes. This durable consumables model supports steadier revenue streams and predictable repurchase demand over multi‑month horizons.
Negative Factors
Sharp revenue and earnings decline
A steep TTM revenue drop and a large net loss represent a significant deterioration in earnings quality and operating leverage. Such a material hit reduces margin cushions, makes recovery dependent on successful execution, and can weigh on sustainable profitability for several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumable business model
Teleflex’s portfolio is concentrated in single‑use devices across high‑acuity therapy areas, creating recurring purchase cycles tied to procedure volumes. This durable consumables model supports steadier revenue streams and predictable repurchase demand over multi‑month horizons.
Read all positive factors
Teleflex (TFX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.48B
Dividend Yield1.11%
Average Volume (3M)745.44K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth-2.75%
EPS Growth-1515.83%
CountryUS
Employees14,100
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.93
Shares Outstanding44,265,385
10 Day Avg. Volume691,065
30 Day Avg. Volume745,437
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.74
Price to Sales (P/S)2.73
P/FCF Ratio22.19
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue2.78
Enterprise Value/Gross Profit5.21
Enterprise Value/Ebitda74.73
Forecast
1Y Price Target
$138.57Price Target Upside5.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)6.7
Revenue Forecast (FY)$2.29B
Teleflex Business Overview & Revenue Model
Company Description
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that compris...
How the Company Makes Money
Teleflex primarily makes money by selling disposable and single-use medical devices and related consumables to hospitals and healthcare providers. Revenue is generated from product sales across its major therapy and procedure areas (e.g., vascular...
Teleflex Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyTeleflex Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
The call outlines a clear strategic transformation with substantial near-term actions: large divestitures that should provide significant proceeds, an aggressive capital return plan ($1.0B buyback) and a planned step-up in R&D to drive future growth. Operationally, RemainCo delivered mid-single-digit revenue growth (4.7% pro forma in 2025) and 2025 adjusted EPS rose 8.7%. However, the company faces meaningful near-term headwinds: roughly $90 million of stranded costs in 2026, margin pressure (2026 operating margin guide ~19% vs. 22.7% in 2025), higher interest expense from acquisition financing, tariff uncertainty (~$18M noted), and execution/timing risk around the closings that enable debt paydown and buybacks. Management expects these are transitional and projects a steady-state operating margin of ~23% and significantly higher adjusted EPS in 2027 once TS/MS agreements and capital deployment occur. Overall, positives (strategic clarity, strong capital returns and long-term margin upside) are balanced by concrete near-term challenges and execution/timing risks.Positive Updates
Strategic Divestitures and Large Expected Cash Proceeds
Signed definitive agreements to sell acute care, interventional urology, and OEM businesses for total cash proceeds of $2.03 billion and expected net after-tax proceeds of approximately $1.8 billion; company intends to use proceeds to repurchase up to $1.0 billion of common stock and pay down roughly $800 million of debt to enhance financial flexibility.
Negative Updates
Stranded Costs and Near-Term EPS Headwind
Management expects approximately $90 million of stranded costs in 2026 related to the divestitures; 2026 adjusted EPS guidance of $6.25 to $6.55 (which excludes benefits from planned $1.0 billion share repurchase and debt repayment) is below 2025 adjusted EPS of $6.98, signaling a near-term earnings decline.
Read all updates
Q4-2025 Updates
Positive
Negative
Strategic Divestitures and Large Expected Cash Proceeds
Signed definitive agreements to sell acute care, interventional urology, and OEM businesses for total cash proceeds of $2.03 billion and expected net after-tax proceeds of approximately $1.8 billion; company intends to use proceeds to repurchase up to $1.0 billion of common stock and pay down roughly $800 million of debt to enhance financial flexibility.
Read all positive updates
Company Guidance
Teleflex’s 2026 guidance for continuing operations calls for pro forma adjusted constant‑currency revenue growth of 4.5%–5.5% (following 4.7% pro forma growth in 2025) and adjusted EPS of $6.25–$6.55, reflecting approximately $90 million of stranded costs in 2026 (with TS/MS agreements expected to fully offset at least $90 million on an annualized basis after deal closings); the company expects 2026 adjusted operating margin of ~19% (steady‑state ~23%, ~400 bps higher once offsets and actions occur), assumes R&D of ~8% of sales (vs ~5% historically), net interest expense of ~ $105M and a ~13.5% tax rate, and does not assume share repurchases in its 2026 guidance (share count roughly consistent with 2025). Management reiterated expected net after‑tax divestiture proceeds of ~ $1.8B, an intention to repurchase $1.0B of stock and use ~ $800M to pay down debt (not reflected in 2026 guidance), noted a restructuring targeting ~ $50M of annual pretax savings (substantially completed by mid‑2028), and said these actions should drive meaningfully higher adjusted EPS in 2027 and beyond (2025 adjusted EPS was $6.98, up 8.7% year over year).Teleflex Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.99B | 3.05B | 2.97B | 2.79B | 2.81B |
| Gross Profit | 1.12B | 1.70B | 1.65B | 1.53B | 1.55B |
| EBITDA | 302.51M | 433.62M | 761.21M | 730.77M | 853.80M |
| Net Income | -905.64M | 69.67M | 356.33M | 363.14M | 485.37M |
Balance Sheet | |||||
| Total Assets | 6.95B | 7.10B | 7.53B | 6.93B | 6.87B |
| Cash, Cash Equivalents and Short-Term Investments | 393.26M | 306.16M | 222.85M | 292.03M | 445.08M |
| Total Debt | 2.73B | 1.76B | 1.93B | 1.83B | 1.97B |
| Total Liabilities | 3.82B | 2.82B | 3.09B | 2.91B | 3.12B |
| Stockholders Equity | 3.12B | 4.28B | 4.44B | 4.02B | 3.75B |
Cash Flow | |||||
| Free Cash Flow | 245.44M | 509.31M | 419.20M | 262.95M | 579.80M |
| Operating Cash Flow | 340.68M | 635.74M | 510.64M | 342.14M | 651.42M |
| Investing Cash Flow | -849.19M | -99.36M | -621.23M | -257.94M | 156.74M |
| Financing Cash Flow | 611.54M | -421.93M | 38.54M | -217.51M | -715.82M |
Teleflex Technical Analysis
Positive
131.58
Price Trends
113.76
Positive
114.35
Positive
117.37
Positive
Market Momentum
4.45
Negative
74.15
Negative
92.56
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TFX, the sentiment is Positive. The current price of 131.58 is above the 20-day moving average (MA) of 117.41, above the 50-day MA of 113.76, and above the 200-day MA of 117.37, indicating a bullish trend. The MACD of 4.45 indicates Negative momentum. The RSI at 74.15 is Negative, neither overbought nor oversold. The STOCH value of 92.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TFX.
Teleflex Risk Analysis
Teleflex disclosed 34 risk factors in its most recent earnings report. Teleflex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Teleflex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $2.50B | 31.80 | 15.58% | 0.95% | 13.53% | 30.00% | |
67 Neutral | $2.79B | 20.99 | 20.26% | ― | -4.02% | 42.52% | |
65 Neutral | $4.07B | 25.02 | 8.52% | ― | 11.34% | 12.26% | |
57 Neutral | $5.48B | -6.01 | -23.70% | 1.11% | -2.75% | -1515.83% | |
57 Neutral | $2.98B | 4,802.44 | 0.04% | ― | -6.24% | ― | |
55 Neutral | $5.67B | -19.89 | -3.41% | ― | 7.85% | 39.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
TFX
Teleflex
121.77
0.27
0.22%
HAE
Haemonetics
59.26
-3.23
-5.17%
ICUI
ICU Medical
118.85
-17.15
-12.61%
LMAT
Lemaitre Vascular
112.04
32.33
40.56%
MMSI
Merit Medical Systems
62.01
-31.94
-34.00%
BLCO
Bausch + Lomb Corporation
16.31
4.94
43.45%
Teleflex Corporate Events
Business Operations and StrategyExecutive/Board ChangesStock Buyback
Teleflex Names Jason Weidman as New CEO
Positive
Apr 30, 2026
On April 30, 2026, Teleflex announced that Medtronic veteran Jason Weidman will become President and CEO effective June 8, 2026, succeeding interim chief Stuart Randle, who remains on the board. Weidman, a 25-year medical device industry leader wi...
Business Operations and StrategyStock BuybackM&A Transactions
Teleflex Reaffirms Strategy Amid Activist Pressure on Board
Positive
Mar 27, 2026
On March 27, 2026, Teleflex reiterated its commitment to shareholder value after activist Irenic Capital urged a public strategic alternatives process and claimed the board was blocking potential acquirers. The company rejected Irenic’s char...
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
Teleflex Clears Key Antitrust Hurdle for OEM Divestiture
Positive
Mar 17, 2026
Teleflex reported that, on December 9, 2025, it entered into an Equity Purchase Agreement to sell its Original Equipment Manufacturing and Development Services business to Lotus US Bidco Inc., an affiliate of Montagu Private Equity and Kohlberg C...
Business Operations and StrategyStock BuybackFinancial DisclosuresM&A Transactions
Teleflex Launches Multi-Year Restructuring to Support Divestitures
Positive
Feb 26, 2026
On February 23, 2026, Teleflex’s board approved a multi‑year restructuring tied to its planned strategic divestitures, aiming to realign its global organization and supply chain, cut stranded costs and rationalize capital assets, large...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.